SLC5A2 and cervical squamous intraepithelial neoplasia: SGLT2 inhibitors may be useful for nephroprotection in patients with elective coronary intervention who will be exposed to contrast media and in diabetic patients who are predicted to be at high risk of developing CIN due to comorbidities.